Biopharma AI
ByCan Sanofi SA’s New AI-Enabled Innovation Hub in China Accelerate Global Drug Development and Reshape Biopharma Operations Across Asia?
Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…
Strategic Industry Release: How AI Companies Led Biopharma Innovation Through Major Collaborations in 2025
Artificial intelligence companies emerged as critical innovation partners for the global biopharmaceutical industry in 2025, reshaping how drugs…
AI in Life Sciences: A Multi-Billion Dollar Transformation Reshaping Drug Discovery and Healthcare
Artificial intelligence is rapidly becoming one of the most transformative forces in the life sciences industry. Global investment…
How Does Eli Lilly Secure $100B+ Obesity Dominance Through 8 Triple/Triple+ Agonist Launches by 2030?
Eli Lilly establishes unrivaled obesity leadership through its 40 Phase 2/3 programs and 34 discovery-stage assets, commanding 60% US GLP-1 market share via Mounjaro/Zepbound ($39.5B 2025 revenue)…
Is the $2.5 Billion Insilico Medicine-Bora Pharmaceuticals Alliance the Blueprint for AI-Native Pharma’s Next Decade?
Key Highlights A Landmark Alliance Bridging AI Discovery and Global Manufacturing In a move set to reshape the…
Can Aspira Women’s Health and Cleveland Clinic’s New AI Alliance Rewrite the Rules for Women’s Diagnostics Across Ovarian Cancer and Beyond?
Key Highlights A Strategic Alliance Built for Scale Aspira Women’s Health and Cleveland Clinic have entered a comprehensive…
